Prescription only · clinician reviewed
PT-141 Injectable
PT-141 for low sexual desire, prescribed and monitored by a clinician.
Member pricing via Castle Rock Contouring
- Billed every 28 days
- Clinician review and care-team messaging included
- We'll bill this supply again when it's due. Complete the portal follow-up so the next fill can ship. You may still have medication on hand.
- Cancel anytime in your patient portal
Free eligibility check · $0 today · You are charged only if a clinician prescribes
Shipping and clinician visit added at checkout.
Choosing a plan starts an intake, not an order. A licensed clinician reviews it and decides whether to prescribe — they may decline, and you are not charged unless they approve.
PT-141 Injectable
PT-141 for low sexual desire, prescribed and monitored by a clinician.
- Desire, not blood flow
- Used as needed
- Clinician assessed
Why people ask about it
What this is for
Targets desire, not blood flow
It acts centrally, so it addresses a different problem than the medications used for erectile function.
Used as needed
It is taken ahead of anticipated activity rather than on a daily schedule.
An option when blood flow drugs are not the issue
For people whose concern is desire, treatments aimed at mechanics often miss the point.
Individual results vary. Your clinician decides whether it is right for you.
Before you start
What to know about PT-141 Injectable
PT-141, also known as bremelanotide, acts on desire pathways in the brain rather than on blood flow. It is used for low sexual desire and is prescribed only after a clinician reviews your history.
- 01
PT-141 is bremelanotide, a melanocortin receptor agonist that acts on desire pathways in the brain rather than on blood flow.
- 02
Bremelanotide is FDA-approved under the brand name Vyleesi for one specific condition: acquired, generalised hypoactive sexual desire disorder in premenopausal women. Any other use is off-label.
- 03
The Phase 3 trials showed meaningful improvements in desire, and nausea was the most common side effect. Your clinician walks through both with you.
- 04
Prescription only, and your clinician may decline after reviewing your blood pressure and cardiovascular history.
Who this tends to fit
- Low sexual desire is your main concern
- You want the possible causes looked at rather than assumed
- You prefer something used as needed
- You want clinician oversight
Fitting the description does not mean you will be prescribed this. A clinician decides after reviewing your intake.
Bremelanotide is FDA-approved under the brand name Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Other uses, and compounded formulations, are off-label and not FDA-approved. Your clinician decides whether it is appropriate for you.
The science
The science of PT-141 Injectable
Tap a card to see the research behind each pathway.
How care works
What clinician oversight means here
Licensed clinicians, real review, and support after you start.
A licensed clinician decides
Your intake is reviewed by a clinician licensed in your state. They choose the treatment and the dose, and they can decline. Insert MD does not make that call.
Dispensed by a licensed pharmacy
Nothing ships without a prescription. Your order is prepared and sent by a licensed pharmacy, not packed by us.
Reviewed again at follow-up
Continuing is a decision, not a default. Your clinician reassesses whether the treatment still fits before you carry on.
Compounded is not FDA-approved
Several treatments here are compounded. The FDA does not review compounded medications for safety, effectiveness, or quality, and we say so on every page where it applies.
How it works
Three steps, no charge to find out
Check eligibility
A quick questionnaire — takes about 2 minutes. No charge to see if you qualify.
Provider review
A licensed clinician reviews your intake and approves an appropriate plan.
Delivered to you
Your treatment ships directly to your door, with care-team support.
Precise, consistent dosing
Your prescription is prepared by a licensed pharmacy and reviewed by a clinician licensed in your state. Nothing ships until they approve.
- Compounded by a licensed pharmacy
- Identity, potency, and purity tested
- Dose set by a licensed clinician
- Ships ready to use — no home mixing
Good to know
PT-141 activates melanocortin receptors in the central nervous system, which are involved in sexual desire. This is a different mechanism from the erectile dysfunction medications that work on blood flow, which is why it is considered when desire rather than mechanics is the issue.
Bremelanotide is FDA-approved under the brand name Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Other uses, and compounded formulations, are off-label and not FDA-approved. Your clinician decides whether it is appropriate for you.
- Pregnant or breastfeeding
- Uncontrolled hypertension
Your dose, schedule, and how long you stay on treatment are set by the prescribing clinician after reviewing your intake, and may differ from any general description here. General information, not medical advice.
Erectile dysfunction medications work on blood flow. PT-141 acts on desire pathways in the brain. They address different problems and are sometimes considered together.
Nausea, flushing, and headache are the most commonly reported, and nausea is the usual reason people stop. Tell your care team how you tolerate it.
A licensed clinician does, after reviewing your intake. Nothing on this page is a prescription or a promise of one, and your plan may look different from any general description here.
References
Scientific sources
The primary papers, for readers who want to go deeper.
- 1.Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.
- 2.Pfaus J, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med. 2007;4 Suppl 4:269-79.
- 3.Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N. Effect of an alpha-melanocyte stimulating hormone analogue on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000;56(4):641-6.
- 4.Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908.
- 5.Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325-37.
- 6.Simon JA, Kingsberg SA, Portman D, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909-17.
- 7.Clayton AH, Lucas J, DeRogatis LR, Jordan R. Phase I randomized placebo-controlled, double-blind study of the safety and tolerability of bremelanotide coadministered with ethanol in healthy male and female participants. Clin Ther. 2017;39(3):514-26.e14.
Plain language
Terms you might hear
- Peptide
- A short chain of amino acids. Most act as signals between cells.
- Melanocortin receptor
- A family of receptors involved in pigmentation, appetite, inflammation, and sexual response. MC4R in the brain is the one relevant here.
- Agonist
- A molecule that binds a receptor and switches it on, as the natural signal would.
- HSDD
- Hypoactive sexual desire disorder — persistently low sexual desire that causes personal distress and is not better explained by another cause.
- PDE5 inhibitor
- The class that includes sildenafil and tadalafil. It works on the blood-flow response, not on desire.
- Off-label
- Prescribing an approved drug outside its approved indication. Legal, common, and a clinical judgement your prescriber makes.
Ready when you are
See if PT-141 Injectable is right for you
A licensed clinician reviews your intake and decides. You are not charged unless they approve.
PT-141 Injectable
$158.00 · $0 today